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Abstract
Joint models for longitudinaland survival data now have along history of being used in clinical 
trials or other studies in which the goal is to assess a treatment effect while accounting for 
longitudinal assessments such as patient-reported outcomes or tumor response. Compared to using 
survival data alone,the joint modeling of survival and longitudinal data allows for estimation of 
direct and indirect treatment effects, thereby resulting in improved efficacy assessment. Although 
global fit indices such as AIC or BIC can be used to rank joint models, these measures do not 
provide separate assessments of each component of the joint model. In this paper, we develop a 
novel decomposition of AIC and BIC (i.e., AIC = AICLong + AICSurv|Long and BIC = BICLong + 
BICSurv|Long) that allows us to assess the fit of each component of the joint model, and in 
particular to assess the fit of the longitudinal component of the model and the survival component 
separately. Based on this decomposition, we then propose ΔAICSurv and ΔBICSurv to determine 
the importance and contribution of the longitudinal data to the model fit of the survival data. 
Moreover, this decomposition, along with ΔAICSurv and ΔBICSurv, is also quite useful in 
comparing, for example, trajectory-based joint models and shared parameter joint models and 
deciding which type of model best fits the survival data. We examine a detailed case study in 
mesothelioma to apply our proposed methodology along with an extensive set of simulation 
studies.
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Through the joint modeling of longitudinal and survival data, researchers may reduce bias in 
the estimates of the treatment effect and also increase the power to compare the efcacy of a 
new oncology treatment with the current standard of care [1, 2]. Although the joint analysis 
of longitudinal and time-to-event outcomes has been widely published in statistical journals, 
it has not yet been routinely applied to the analysis of patient-reported outcomes (PROs) for 
the purpose of evaluating the efcacy and tolerability of cancer treatment. One barrier to the 
implementation of these methods has been the lack of usable sofitware to guide the 
programming and evaluation of these joint models. Building on previous joint modeling 
work in a highly symptomatic and particularly fatal condition [malignant pleural 
mesothelioma (MPM)] [3, 4], we develop methods to evaluate model fit in order to identify 
proper model specification.
This work was motivated by the need to adequately assess the differential benefits of 
alternative medical treatments, particularly in oncology applications where the survival 
advantage between competing medications may be modest. In this setting, information from 
the patients’ perspectives can be useful in evaluating actual patients’ experiences on 
dimensions known to be important to them and also associated with treatment outcomes. 
Accordingly, the field of PROs has evolved and has reached a common understanding about 
good clinical practices for the use of PROs [5]. Additionally, the U.S. and European 
regulators have published guidance on the use of these measures to support PRO-based 
claims in pharmaceutical product labeling (European Medicines Agency, 2005; US Food 
and Drug Administration Guidance for Industry, 2009)[6]. Unfortunately, relatively little 
attention has been paid to similarly advancing the analysis of trial-based PRO data; the 
inclusion of PRO assessments is seldom done with the rigor used to specify and analyze 
traditional endpoints of survival and tumor response [7]. Hence, the benefits of good PRO 
practice standards and insightful regulatory guidance have not generally led to informative 
conclusions. Published results concerning the use of joint survival/PRO models should help 
inform decision makers about the impact of anticancer treatment on both survival and 
patient well-being [3, 4, 8]. Joint modeling of these endpoints can provide a comparative 
assessment of patient-reported changes in specifc symptoms or global measures (e.g., 
quality of life or functioning) that correspond to treatment-related changes in survival. 
Therefore, it could be shown that increased survival was accompanied by relatively better 
PRO scores or alternatively that extended progression-free or overall survival was 
experienced at the expense of well-being. To support this joint modeling, we show how to 
evaluate the distinct effects of longitudinal and time-to-event outcomes on the fit of the joint 
model, and we develop the necessary SAS code to facilitate use of these methods.
The literature on joint modeling of longitudinal and survival data has burgeoned to the point 
that it is impractical to make broad general conclusions based on a systematic review of the 
literature. It is, however, practical and useful to describe the two basic fundamental 
approaches in joint modeling of longitudinal and survival to achieve this goal. The first is 
the "trajectory model" (TM) approach, where the trajectory function (mean response) from 
the longitudinal model is substituted into the hazard function of the survival model, thereby 
serving as a time-varying covariate in the survival model. The second basic approach is the 
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"shared parameter model" (SPM), where the longitudinal model and survival model share 
common random effects which then induces correlation between the longitudinal and 
survival components. Both modeling schemes have advantages and disadvantages. The TM 
advantage, compared to the SPM, is that it leads to a straight forward interpretation of the 
association between the longitudinal marker and survival time through the direct inclusion 
of the trajectory function in the hazard. For the SPM, the characterization of the association 
is much more complex and can only be analytically determined once the random effects 
have been integrated out, since the two components of the model are independent 
conditional on these random effects. Typically, this integration cannot be carried out in 
closed form, and even if it were, the resulting dependence structure would be very 
complicated involving lots of parameters and resulting in difcult interpretations.
There have been many papers in the statistical literature concerning these two basic 
approaches. The TM in joint modeling for cancer vaccine trials in malignant melanoma has 
been considered in [9, 10, 11, 12]. The TM models have been also used in quality-of-life 
studies [13, 14, 15, 16], and in AIDS studies [17, 18, 19, 20, 21, 22, 23]. The SPM models 
have been used in other types of biomedical applications [24, 25]. There has been much 
work on using the SPM in joint modeling of survival and longitudinal data focused on AIDS 
studies, and in particular, jointly modeling of survival data and univariate or multivariate 
longitudinal CD4 counts. These articles include [26, 27, 28]. Other researchers who have 
used SPM’s with a multivariate longitudinal response include [29, 30, 31, 32]. An excellent 
general review on joint modeling of longitudinal and survival data was given in [33]. 
Ibrahim, Chen, and Sinha ([34], Chapter 7) also gave an overview of joint modeling 
methods. Joint models for longitudinal and survival data in which the survival component of 
the model is a cure rate model were considered in [35, 10, 11], where the models focus on 
cancer clinical trials.
One important issue in the joint modeling of longitudinal and survival data concerns the 
separate contribution of the model components to the overall goodness-of-fit of the joint 
model. In this paper, we derive a novel decomposition of the AIC and BIC criteria into 
additive components that will allow us to assess the goodness of fit for each component of 
the joint model. More importantly, such a decomposition allows us to develop ΔAICSurv and 
ΔBICSurv to quantify the change of AIC and BIC in fitting the survival data with and 
without the longitudinal data. Thus, ΔAICSurv and ΔBICSurv can be used to determine the 
importance of the longitudinal data to the model fit of the survival data. In addition, 
ΔAICSurv and ΔBICSurv are also very useful in assessing whether a linear trajectory or 
quadratic trajectory is more suitable and in facilitating a direct comparison between TM’s 
and SPM’s. These proposed measures will help the data analyst in not only assessing each 
component of the joint model but also in determining the contribution of the longitudinal 
data to the fit of the survival data.
The rest of the paper is organized as follows. A detailed description of the longitudinal and 
survival data from a clinical trial is given in Section 2. The joint models, the time-varying 
covariates models, and the two-stage models are presented in Section 3 along with their 
properties. The proposed decomposition of AIC and BIC is developed in Section 4. An 
extensive simulation study is conducted in Section 5, and a comprehensive analysis of the 
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longitudinal and survival data described in Section 2 is given in Section 6. We conclude the 
paper with a discussion including some proposed extensions to our research in Section 7.
2. The EMPHACIS Data
Our research was motivated by the large phase III multicenter, randomized, single-blind, 
EMPHACIS lung cancer clinical trial (Evaluation of MTA in Mesothelioma in a Phase 3 
Study with Cisplatin). Although the details of this study have been published elsewhere 
[36], we provide the essential background information needed for contextual understanding 
of our proposed methodology. The study drug was pemetrexed (PEM), a multi-targeted 
antifolate (MTA), which was given in combination with cisplatin (Cis) (the PEM/Cis arm), 
and the active-treatment comparator was cisplatin alone (the Cis arm); respectively, 226 and 
222 patients received at least one cycle of chemotherapy. The treatment for both arms was 
structured as six 21-day cycles of therapy; patients receiving treatment benefit could receive 
additional cycles based on investigator discretion.
Malignant pleural mesothelioma is characterized by rapid disease progression, high 
symptom burden, and a relatively short median survival of 12 months afiter diagnosis [37, 
38]. Accordingly, patient-reported assessments are important for evaluation of disease 
progression and patients’ response to therapy. In oncology, the patients’ importance ratings 
on the magnitude of progression-free survival improvement has been shown to depend on 
the severity of disease-related symptoms [39]. We analyzed the disease-specifc patient-
reported Lung Cancer Symptom Scales (LCSS) [40] to evaluate the patient-level association 
of five of the six instrument items (i.e., anorexia, cough, dyspnea, fatigue, and pain) with 
progression-free survival using the EMPHACIS trial data. The sixth LCSS symptom, 
hemoptysis, was not analyzed due to research suggesting that this phenomenon is not 
prevalent in MPM [41]. The three remaining LCSS items are global constructs (interference, 
quality of life, symptoms), and due to their non-specifcity, we also excluded these from our 
analysis. Each questionnaire item was assessed using l00-mm visual analogue scales (0=no 
symptoms, 100 = worst possible symptoms). There were two measurements at baseline. In 
our analysis, we took the average of the two baseline measurements of each longitudinal 
outcome as the baseline outcome and reset the measurement time so that the baseline 
measurement time is zero. Weekly measurements (at days 8 ± 1, 15 ± 1, l9) were taken in 
each 21-day therapy cycle. The LCSS was also assessed approximately every 3 months 
afiter the patient had received his or her last dose of treatment if the patient had not initiated 
subsequent therapy. Progression free survival time (PFS) is defined as the time from 
randomization to the time until documented progression or death from any cause. Beyond 
disease progression, very few LCSS assessments were available.
Previously, researchers have investigated the prognostic effect of baseline PRO outcomes on 
overall survival in patients with MPM [42]. We are, however, interested in the association 
between post-baseline PRO scores and PFS. The main goal of applying joint models in this 
study is to assess the association of each longitudinal LCSS symptom with PFS and the 
treatment effects on each LCSS item and PFS simultaneously. More importantly, with the 
novel decomposition of AIC and BIC, the longitudinal LCSS symptoms can be compared in 
terms of their contribution to the overall fit of the survival data.
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Our cohort consists of 425 patients with at least one post-baseline value for each 
longitudinal outcome. The covariates we consider in this study include race/ethnicity, 
gender, age, Karnofsky status, baseline stage of disease, vitamin supplementation, and 
treatment assignment. Table 1 shows the baseline characteristics of the patients in each 
treatment group and the four descriptive statistics (minimum, median, maximum and mean) 
for PFS.
3. The Models
Suppose that there are n subjects. For the ith subject, let Yi(t) denote the longitudinal 
outcome, which is observed at time t ∈{ai1, ai2,...., aimi}, where ai1 = 0 <ai2 < ... <aimi and 
mi > 1. Note that Yi(0) corresponds to the baseline value. Let ti denote the failure time, 
which may be right-censored, and let δi be the censoring indicator such that δi = 1 if ti is a 
failure time and 0 if ti is right-censored for the ith subject. Also let zi be the treatment 
indicator such that zi = 1 for the treatment and zi = 0 for the control. We further let xi denote 
the p-dimensional vector of covariates. We first consider the joint model for (Yi, ti), which 
consists of the longitudinal component and survival component presented in Subsections 3.1 
and 3.2. We also consider a time-varying covariates (TVC) model for ti, where Yi(t) is 
treated as a time-varying covariate in Subsection 3.3.
3.1. Longitudinal Component of the Joint Model
For the ith subject, we assume a mixed effects regression model for the longitudinal 
outcome Yi(t), which is given by
(3.1)
where  is a polynomial vector of order q for j = 1,..., mi, θi is a 
(q+1)-dimensional vector of random effects, and γ2 is a p-dimensional vector of regression 
coefficients. In (3.1), we further assume θi ~ N(θ, Σ), where θ is the (q+l)-dimensional 
vector of overall effects, Σ is a (q+1)×(q+1) positive definite covariance matrix with lower 
triangle consisting of {Σ00, Σ10, Σ11,..., Σqq}, εi(aij) ~ N(0, σ2), and θi and εi(aij) are 
independent. We note that in (3.1), if q = 1, g(aij) = (1,aij)′ and  yields a linear 
trajectory, and if q = 2,  and  leads to a quadratic trajectory.
3.2. Survival Component of the Joint Model
For failure time ti, we assume the hazard function is of the general form
(3.2)
where λ0(t) is the baseline hazard function, h(·) is a linear function of θi, g(t), γ1zi, and 
with β being a vector of the corresponding regression coefcients, , and 
. Note that in (3.2), θi, g(t), γ1, and γ2 are the parameters or the functions from 
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the longitudinal component of the joint model in (3.1), and λ0, β, α1 and α2 are the only 
parameters pertaining to the survival component. When
(3.3)
where h*(·) is a linear function of , γ1zi, and , (3.2) leads to the TM. In this case, 
the hazard function depends on θi and g only through . When h does not depend on g(t), 
that is,
where h*(·) is a linear function of , γ1zi, and , (3.2) reduces to the SPM.
In (3.2), we further assume a piecewise constant hazard model for λ0(t). Specifcally, we first 
construct a finite partition of the time axis, 0 = s0 < s1 < s2 < ... < sK−1 < sK = ∞. Thus, we 
have K intervals (0,s1], (s1,s2], ... , (sK−1,sK]. Then, we assume a constant baseline hazard 
within each of the K intervals, that is,
(3.4)
Finally, we write λ = (λ1,...,λK)′. Using (3.4), the complete-data likelihood function for the 
survival component for the ith subject can be written as
(3.5)
where λ(t|λ0, β, α, θi, g(t), γ,zi, xi) is given in (3.2).
Remark 3.1 In (3.2), when β = 0,  and the hazard function 
reduces to . In this case, we fit 
the survival data alone (without the longitudinal data) and the likelihood function in (3.5) for 
the ith subject reduces to
(3.6)
3.3. The Time-Varying Covariates (TVC) Model
If ti is of primary interest, the time-varying covariates model (see, for example, [43, 44]) can 
be used to model the failure time ti, in which Yi(t) can be considered as a time-varying 
covariate. Under the TVC model, the hazard function is assumed to be
(3.7)
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where λ0(t) is the baseline hazard function. Since the longitudinal outcome Yi(t) is observed 
only at each of ai1, ... , aimi, we let Yi(t) = Yi(aij) for aij ≤ t <ai,j+1 for j = 1, ... , mi, where 
ai,mi+1 = ∞. Similar to (3.2), a piecewise constant hazard model in (3.4) is assumed for λ0(t) 
in (3.7). Finally, we notice that in the TVC model (3.7), Yi(t) is a one-dimensional covariate 
and therefore, β is one-dimensional as well.
3.4. The Two-Stage (TS) Model
Instead of directly using the longitudinal outcome Yi(t) as a covariate in (3.7), (i) we first fit 
(3.1) to the longitudinal data alone, obtain the estimates of θi, γ1, and γ2, denoted by , 
and ; and compute ; and (ii) we then use  as a time-
varying covariate in the survival model, in which the hazard function is defined as 
. At first, it appears that the 
above hazard function is similar to (3.7). However, there is a substantial difference between 
Yi(t) and . The longitudinal outcome Yi(t) is observed only at each of the time points 
ai1, ..., aimi while  is defined at any time t. In addition,  is much less variable than 
Yi(t) since  is a smooth function of t and Yi(t) is random. The model defined here is 
known as the two-stage (TS) model [33].
4. Assessing the Contribution of Longitudinal Data When Modeling the 
Survival Data
For the joint model discussed in the previous section, we develop a new method to assess the 
contribution of the longitudinal data when fitting the survival data. We first introduce some 
notation. We rewrite (3.1) as follows:  where Y i =(Yi(ai1),...,Yi(aimi))' , 
Wi is a mi by (p + q + 2) matrix whose ith row is , and εi 
=(εi(ai1),...,εi(aimi))’ ~ N(0,σ
2Imi). The complete-data likelihood function of the longitudinal 
outcomes for the ith subject is given by
(4.1)
for i = 1,...,n. Note that the density of θi is given by
(4.2)
Let φ = (λ, β, α, γ,σ2, θ, Σ). Using (3.5), (4.1), and (4.2), the observed-data likelihood 
function for (Yi,ti,δi) for the ith subject is given by
(4.3)
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for i = 1,..., n. Let  denote the maximum likelihood estimate (MLE) of φ from the joint 
model. Using (4.3), the Akaike Information Criterion (AIC) [45] for the joint model is given 
by
(4.4)
and the Bayesian Information Criterion (BIC) [46] is defined as
(4.5)
4.1. AIC and BIC Decomposition
To assess the contribution of longitudinal data to the fit of the survival data, we need to 
decompose AIC in (4.4) into two parts: one part for the longitudinal data and the other part 
for the survival data conditional on the longitudinal data. Write φ1 =(γ,σ2, θ, Σ) and φ2 =(λ, 
β, α). We are led to the following theorem.
Theorem 4.1 Let f(θi|Y i,Wi, φ1) be the conditional density of the random effects θi given 
Y i, and also let , which is the likelihood 





and  and  are the MLEs of  and .
The proof of Theorem 4.1 is given in the Appendix. BIC in (4.5) has a similar 
decomposition as in (4.6); this result is stated in the following corollary, and the proof of 
this corollary directly follows that of Theorem 4.1.
Corollary 4.1 BIC in (4.5) can be decomposed as BIC = BICLong + BICSurv|Long, where 
BICLong = AICLong + dim(φ1)(log n − 2), and BICSurv|Long = AICSurv|Long + dim(φ2)(log n − 
2).
Remark 4.1 We note that the AIC decomposition in (4.6) and the BIC decomposition in 
Corollary 4.1 hold for general longitudinal data models, which may not be normal. 
However, for normally distributed longitudinal data, f(θi|Yi,Wi, φ1) and L(φ1|Yi,Wi) in 
Theorem 4.1 are available in closed form. It is easy to see that
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Thus, the observed-data likelihood function of the longitudinal data takes the form:
(4.7)
After some algebra, we also obtain the conditional distribution of the random effects θi 
given the longitudinal data, which is given by
Remark 4.2 SPM and TM discussed in Section 3 can be implemented in SAS via PROC 
NLMIXED. The NLMIXED procedure calculates , , and the overall AIC using adaptive 
Gaussian quadrature to approximate (4.3). For normally distributed longitudinal data, 
AICLong can be computed using (4.7) and , which may be implemented in SAS via PROC 
IML. Subsequently, AIC–AICLong gives AICSurv|Long. Alternatively, given  and , we 
may use a Monte Carlo (MC) method to compute AICSurv|Long using (4.6) and an MC 
sample generated from . This alternative approach can be used to validate 
the total AIC obtained from PROC NLMIXED.
4.2. ΔAICSurv and ΔBICSurv
AICLong (BICLong) measures the contribution to the total AIC (BIC) due to the longitudinal 
data while AICSurv|Long (BICSurv|Long) quantifes the contribution to the total AIC (BIC) due 
to the survival data with the additional information from the longitudinal data. Let
(4.8)
where L0(λ, α|ti,δi,zi, xi) is defined by (3.6). We now propose the following two model 
assessment criteria:
(4.9)
Both ΔAICSurv and ΔBICSurv measure the gain of the fit in the survival component due to 
the longitudinal data with a penalty for the additional parameters in the survival component 
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of the joint model. The model with a large value of ΔAICSurv (ΔBICSurv) is more preferred. 
To address an important practical issue of how ΔAICSurv and ΔBICSurv are related to the 
magnitude of the longitudinal outcomes, we establish a useful result, which is formally 
stated in the following theorem.
Theorem 4.2 The criteria ΔAICSurv and ΔBICSurv are invariant to location and scale 
transformations of the longitudinal outcomes. Specifcally, consider a linear transformation: 
 for j =1,...,mi and i = 1,...,n, where b and c > 0 are two known 
constants. The resulting criteria corresponding to the transformed longitudinal outcomes 
's are denoted by ΔAICSurv(b, c) and ΔBICSurv(b, c). Then, we have ΔAICSurv(b, c)= 
ΔAICSurv and ΔBICSurv(b, c) = ΔBICSurv for all −∞ <b< ∞ and c > 0.
The proof of Theorem 4.2 is given in the Appendix. We note that if  and c = S, where 
 and , then the 's are the 
standardized longitudinal outcomes. This linear transformation invariant property of 
ΔAICSurv and ΔBICSurv allows us to standardize the longitudinal outcomes to improve 
numerical stability in fitting the joint model of the longitudinal and survival data as well as 
computing ΔAICSurv and ΔBICSurv using existing statistical sofitware such as SAS.
5. Simulation Studies
In this section, we conduct extensive simulation studies to examine the empirical 
performance of ΔAICSurv and ΔBICSurv in model comparison as well as in the determination 
of the contribution of the longitudinal data to the goodness-of-fit of the survival model. In 
the simulation studies, we consider four types of models, namely, SPM, TM, TS and TVC 
models. Although the definitions of ΔAICSurv and ΔBICSurv are based on the joint model, 
they can be extended to the TS and TVC models as well. Specifcally, for the TVC model, 
AIC is given by
(5.1)
where 
and λ(t|λ0, β, α,zi, xi, Yi(t)) is given in (3.7). We define ΔAICSurv as follows: ΔAIC = 
AICSurv,0 − AICSurv|Y, where AICSurv,0 is given by (4.8). ΔBICSurv can be defined in a 
similar fashion. Replacing Y by  in (5.1), ΔAICSurv and ΔBICSurv can be defined for the 
TS model.
Three simulation studies are considered (i) to examine the performance of ΔAICSurv and 
ΔBICSurv in selecting the true model (Simulations I and II) and determining the true 
longitudinal outcome that is most related to the survival model (Simulation III); (ii) to 
investigate the empirical properties of the maximum likelihood estimates of the parameters 
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in the joint model (Simulations I and II); and (iii) to test the robustness of the computational 
procedure to the dimension of the model parameters (Simulation II). In all three simulation 
studies, we independently generate 500 simulated datasets, and in each dataset there are n = 
400 subjects. The treatment indicator zi is generated from a Bernoulli(0.5) distribution. The 
time points aij’s at which the longitudinal outcomes are taken are fxed at (0, 21, 42, 63, 84, 
105, 126)/30.4375, where 30.4375 is the average number of days in each month and is 
obtained by 365.25/12. Other data generation details are given as follows.
Simulation I: The true model is SPM with linear trajectory denoted by SPML. Specifcally, 
the longitudinal data is simulated from a N(μi(aij),σ2) distribution, where μi(aij) = θ0i + θ1iaij 
+ γzi, and ti* is generated from [−λexp{β1(θ0i + γzi)+ β2θ1i + αzi}]−1log(1 − U), where U ~ 
U(0, 1). The design values of the parameters are given in Table 2. The censoring time Ci is 
generated from an exponential distribution with mean 100. The right censoring percentage is 
roughly 8% which mimics the real data analysis. The failure time and censoring indicator 
are calculated as  δi and  and 0 otherwise.
Simulation II: The true model is SPM with quadratic trajectory denoted by SPMQ. The 
data generation process follows the same steps as in Simulation I. The design values of the 
parameters are shown in Table 2.
Simulation III: The same setting as in Simulation I is used to generate the longitudinal data 
and survival times under the true model SPML. This dataset is denoted by DLong. We also 
generate three additional sets of longitudinal data, which are associated with the one 
generated in Simulation I. These additional longitudinal trajectories are simulated from 
, where , and then the 
longitudinal data are generated from N(μli(aij), 0.52) for l =1, 2, 3, where σ1 = 0.1, σ2 = 0.5, 
and σ3 = 1. These three sets of longitudinal data each are coupled with the same survival 
times as in DLong to form four additional datasets. These resulting datasets are denoted by 
DLong1,...,DLong3.
In Simulation I, we fit SPML, TML (TM with linear trajectory and 
 in (3.3)), the TS model with linear trajectory, 
and the TVC model (all with K = 1, where K is defined in (3.4)) to each simulated dataset. In 
Simulation II, we fit SPML, SPMQ, TML, TMQ (TM with quadratic trajectory), the TS 
model, and the TVC model to each simulated dataset. In Simulation III, we fit SPML to each 
of the datasets DLong, DLong1, DLong2, DLong3 and the corresponding results are labeled as 
Long, Longl, Long2, and Long3.
In both Simulations I and II, we compute the estimates of the parameters under the true 
models. Let η denote a parameter in the true model. Also let  and  be the MLEs of η 
and the standard error of  from the bth simulated dataset for b =1, 2,..., 500. We define the 
simulation estimate (EST) and the standard error (SE) to be  and 
. We also define the simulation standard deviation (SD) and the root of the 
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mean squared error (RMSE) as  and 
, where η*is the true value of η. Finally, we define the coverage 
probability (CP) of the 95% confidence intervals as , where Lb and 
Ub are the 95% lower and upper limits in the bth simulation. The ESTs, SEs, SDs, RMSEs, 
and CPs for the parameters in SPML and SPMQ are reported in Table 2. From this table, we 
see that for all parameters, the ESTs are very close to the corresponding true values, the SEs 
are very close to the SDs, and the CPs are always around 95% under both SPML and SPMQ.
Suppose we compare a total of J candidate models. Let ΔAICSurv,jb and ΔBICSurv,jb denote 
the values of ΔAICSurv and ΔBICSurv from the bth simulated dataset. Then, the frequency of 
ranking Model j as the best according to ΔAICSurv criterion is defined as 
 A similar frequency can be defined for 
the ΔBICSurv criterion or the other criteria. If Model l is the true model, the average 
misspecification rate according to ΔAICSurv is given by 
.
Table 3 shows the means of ΔAICSurv and ΔBICSurv as well as the frequencies of ranking 
each model as best based on ΔAICSurv and ΔBICSurv for 500 simulated datasets for all three 
simulations. In Simulations I and III, the true model is SPML with K = 1 while the true 
model is SPMQ with K = 1 in Simulation II. In all three simulations, the true model always 
has the largest mean of either ΔAICSurv or ΔBICSurv and the highest frequency of ranking 
the true model as best based on either ΔAICSurv or ΔBICSurv. The average misspecification 
rates according to ΔAICSurv and ΔBICSurv in Simulation I, II, and III are 0.24 and 0.538, 
0.058 and 0.272, 0.136 and 0.136, respectively. We also see from Table 3 that the 
differences in the means of ΔAICSurv between SPML and TML or SPMQ and TMQ are 
greater than the differences in the means of ΔBICSurv. These results are expected since TML 
and TMQ have fewer regression coefcients than SPML and SPMQ, and BIC penalizes the 
dimension of the parameters more than AIC. Similar results are observed based on the 
frequency of ranking each model as best. Thus, the performance of ΔAICSurv is slightly 
better than ΔBICSurv in correctly identifying the true model. It is interesting to note that 
although neither TM nor the TS model is the true model, TM outperforms the TS model in 
both Simulations I and II. In Simulations I and II, the TVC model fits the data the most 
poorly based on both ΔAICSurv and ΔBICSurv.
In Simulation III, the true longitudinal outcome is Long, and Longl is obtained by adding 
random errors to both the random intercept and slope of the linear trajectory in Long for l = 
1,..., 3. Longl to Long3 become gradually further apart from Long since the standard 
deviation of the random errors increases from 0.1 to l. Since we fit the same model to each 
of these five datasets, the differences between ΔAICSurv and ΔBICSurv are the same for 
Long, Longl, ... , Long3. Thus, only the results based on ΔAICSurv are reported in Table 3. 
We see from this table that Long has the largest mean of ΔAICSurv and the highest 
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frequency of ranking Long as best, and the mean and frequency corresponding to Longl 
decrease as l increases. The results for Long and Long1 are very close, which is expected 
since Longl is obtained by adding a very small amount of noise to Long.
In addition, Figure 1 shows the boxplots of the ΔAICSurv and ΔBICSurv differences between 
the true model and the competing models, respectively. From Figure 1 (a), (b), and (c), we 
see that most of these boxes are above zero, which indicates that the true model does fit the 
data much better than the competing models based on ΔAICSurv. All boxes for ΔBICSurv 
differences in Figure 1 (e) are also above O. However, the medians of the ΔBIC differences 
between SPML and TML or between SPML and TS shown in Figure 1 (d) are very close to 
O. These results are consistent with those based on the means of ΔAICSurv and ΔBICSurv 
and the frequencies of ranking each model as best.
6. Analysis of the EMPHACIS Data
In this section, we carry out a detailed analysis of the EMPHACIS data using the models 
discussed in Section 3 and the ΔAICSurv and ΔBICSurv criteria proposed in Section 4. As 
stated in Section 2, data from n = 425 patients are used, and the longitudinal and survival 
data we consider are one of five patient-reported LCSS outcomes corresponding to anorexia, 
cough, dyspnea, fatigue, and pain along with progression free survival time in months. The 
treatment indicator zi = 1 if the ith patient received pemetrexed/cisplatin and zi = 0 if the ith 
patient received cisplatin alone, and the covariates (Table l) include race (xi1), gender (xi2), 
age (xi3), Karnofsky status (xi4), baseline stage of disease (xi5), and vitamin supplementation 
(xi6). All six covariates (p = 6) are binary, each taking a value of 0 or 1. Specifcally, xi1 = 1 
if white, xi2 = 1 if male, xi3 = 1 if age ≥ 65, xi4 = 1 if Karnofsky status is high, xi5 = 1 if stage 
I/II, and xi6 = 1 if full vitamin supplementation. In all calculations, we standardized all five 
patient-reported LCSS outcomes. The LCSS original-scaled item means (standard 
deviations) were 30.79 (27.19), 11.48 (17.93), 31.41 (26.33), 39.38 (27.06), and 24.64 
(24.90) for anorexia, cough, dyspnea, fatigue, and pain, respectively. The total numbers of 
completed longitudinal assessments (i.e., ) including the baseline measurements 
were 5504, 5544, 5553, 5530, and 5546 for anorexia, cough, dyspnea, fatigue, and pain.
We fit the SPML, SPMQ, TML, TMQ, TS and TVC models, where SPML, SPMQ, TML, 
and TMQ are defined in Section 5, to the PFS data paired with one of the five LCSS 
longitudinal outcomes corresponding to anorexia, cough, dyspnea, fatigue, and pain. As 
suggested by an anonymous referee, we also considered the joint model with a quadratic 
trajectory in the longitudinal component and only a linear trajectory in the the survival 
component, where the models corresponding to SPMQ and TMQ are denoted by SPMQL 
and TMQL. The six covariates (xi’s) and the treatment indicator were included in all the 
models we estimated. As shown in Table 1, the maximum values of PFS were 27.1 and 21.8 
months for the pemetrexed/cisplatin arm and the cisplatin alone arm, respectively. For all the 
models, we used the piecewise constant hazard model given in (3.4) for the baseline hazard, 
and the partition intervals were constructed based on the percentiles such as the first (Q1), 
second (Q2), and third (Q3) quartiles of the PFS times.
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We used the ΔAICSurv and ΔBICSurv criteria as well as the AICSurv|Long and BICSurv|Long 
criteria to determine the number of intervals (K) in (3.4). We first fit the PFS data alone 
using (3.6). The values of AICSurv,0 and BICSurv,0 defined by (4.8) were 2225.80 and 
2258.22 for K = 1, 2206.29 and 2242.76 for K = 2, and 2209.71 and 2254.28 for K = 4. We 
considered two methods for constructing the three intervals: inserting two intervals within 
the first interval or the second interval using the piecewise constant hazard model with K = 
2. The resulting piecewise constant hazard models with (s0 = 0, s1 = Q1, s2 = Q2) and (s0 = 
0, s1 = Q2, s2 = Q3) are denoted by K = 3(1) and K = 3(2). Similarly, we constructed the 
partitions for K > 3. This approach is desirable when more events occur early in the follow-
up. Another advantage of this approach is that the resulting partitions are nested and, hence, 
the log-likelihood of the joint model increases in K when the longitudinal component 
remains fxed. The values of AICSurv,0 and BICSurv,0 were 2208.27 and 2248.79 for K = 3(1) 
and 2207.73 and 2248.25 for K = 3(2). These results indicate that when we fit the PFS data 
alone, the piecewise constant hazard model with K = 2 fits best according to both AICSurv,0 
and BICSurv,0. We then fit the PFS data and the LCSS longitudinal data jointly. For ease of 
presentation, we discuss the case for the longitudinal outcomes corresponding to pain only 
since the results were similar for anorexia, cough, dyspnea, and fatigue. Figure 2 shows the 
MLEs of λ and the values of AICSurv|Long and BICSurv|Long for K = 1, 2, 3, and 4 under 
SPML. From Figure 2, we see that AICSurv|Long and BICSurv|Long were 2199.30 and 2239.82 
for K = 1; 2161.84 and 2206.42 for K = 2; 2l63.01 and 2211.64 for K =3(1); 2163.84 and 
2212.47 for K = 3(2); and 2164.98 and 2217.66 for K = 4, respectively. Clearly, the best 
values of AICSurv|Long and BICSurv|Long were obtained under SPML with K = 2. Thus, 
according to AICSurv|Long and BICSurv|Long, SPML with K = 2 fits the PFS data the best. We 
also see from Figure 2 that for K = 2, λ2 =0.276 is much larger than λ1 = 0.138, indicating 
that the exponential model (i.e., K = 1) did not fit the PFS data well. All of the above results 
suggest that it is sufcient to choose K = 2 in fitting the PFS data. We note that the issue of 
interval choice has also been discussed in [47], [48], and [49].
Table 4 shows AIC, AICLong, ΔAICSurv, BIC, BICLong, and ΔBICSurv for SPML, SPMQ, 
SPMQL, TML, TMQ, and TMQL and ΔAICSurv and ΔBICSurv for the TVC and TS models. 
The ΔAICSurv’s and ΔBICSurv’s are plotted in Figure 3. We see from Table 4 that pain had 
the largest values of ΔAICSurv and ΔBICSurv under SPML, SPMQ, SPMQL, TML, TMQ, 
TVC, and TS; fatigue had the largest values of ΔAICSurv and ΔBICSurv under TMQL and 
the second largest values of ΔAICSurv and ΔBICSurv under the other seven models; and 
cough had the smallest values of ΔAICSurv and ΔBICSurv. These results indicate that pain 
led to the most gain in fitting the PFS data while cough had the least contribution to the fit of 
the PFS data. However, AIC and BIC were not able to determine the contribution of the 
longitudinal data in fitting the survival data for these five sets of LCSS longitudinal 
outcomes under the joint modeling framework. We observe from Table 4 that the smallest 
values of AIC and BIC were attained by dyspnea under SPML, SPMQ, TML, and TMQ. 
Afiter examining AIC Long and BICLong, we found that dyspnea had the smallest values of 
AICLong and BICLong. Thus, AICLong and BICLong were the main contributions to the 
smallest values of AIC and BIC for dyspnea. From Table 4, we also see that (i) the values of 
ΔAICSurv under SPMQ are greater than those under SPMQL for anorexia, cough, dyspnea, 
and pain while the value of ΔAICSurv under SPMQ is very similar to the one under SPMQL 
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for fatigue; and (ii) the values of ΔBICSurv under SPMQL are greater than those under 
SPMQ for anorexia, cough, dyspnea, and fatigue due to the extra parameter in the survival 
component under SPMQ. However, the values of ΔAICSurv and ΔBICSurv under TMQ are 
consistently higher than those under TMQL since under the TM, both TMQ and TMQL 
share the same number of parameters in the survival component. We note that on the one 
hand, ΔAICSurv and ΔBICSurv are defined primarily based on the likelihood function of the 
survival data; on the other hand, AIC and BIC are constructed using the likelihood function 
of both the longitudinal and survival data. Thus, since the total number of longitudinal 
outcomes were different among these five symptoms, AIC and BIC were indeed not 
comparable among them. Within each of these five symptoms, AIC and BIC selected SPMQ 
over SPML and TMQ over TML, due to the fact that AIC Long and BIC Long were in favor 
of quadratic trajectories over linear trajectories. These results indicate that the quadratic 
trajectories fit the longitudinal data better.
Tables 5 and 6 show the hazard ratios (HR’s, the exponentiated parameters) and p-values of 
the direct treatment effect on PFS (α), the overall treatment effect (α* = α1 + β1γ1 or α* = α1 
+ βγ1), and the regression coefficients β associated with random trajectories under SPML, 
SPMQ, SPMQL, TML, TMQ, and TMQL. From these two tables, we see that except for 
cough and dyspnea, the HR’s for the overall treatment effect on PFS that ranged from 0.620 
to 0.645 for the joint model were smaller than the HR of 0.647 when we fit the PFS data 
alone. It is interesting to mention that under TML and TMQ, the order in the magnitude of 
the HR’s for β is consistent with the values of ΔAICSurv and ΔBICSurv. For example, pain 
had the largest HR’s, namely, 1.464 and 1.5O4 under TML and TMQ, while cough had the 
smallest HR’s, namely, 1.194, 1.237, and 1.019 under TML, TMQ and TMQL.
7. Discussion
We have proposed novel decompositions of AIC and BIC to individually assess the 
contributions of each component in joint models of longitudinal and survival data, and we 
use ΔAICSurv and ΔBICSurv to determine the contribution of the longitudinal data to the fit 
of the survival data. We conducted extensive simulation studies to examine the empirical 
performance of ΔAICSurv and ΔBICSurv and demonstrated our proposed methodology on a 
detailed case study in mesothelioma. The proposed methodology is quite useful in also 
comparing and choosing between a trajectory-based model or a shared parameter model, 
which is important, since these two classes of models are often used and the choice of which 
one to use is not always clear. Our proposed criteria also help in the assessment of the 
survival model, in determining how many intervals to choose, for example, in the piecewise 
constant hazard model.
All computations in Section 5 and 6 were done in SAS. PROC NLMIXED was used to 
obtain the MLEs and AIC, and PROC IML was used to compute AICLong. The Riemann 
integral was used to compute the cumulative hazard function in (3.5) for the trajectory 
models. The Monte Carlo (MC) method for estimating AICSurv|Long discussed in Remark 4.2 
was also implemented in PROC IML. As an illustration, for anorexia, cough, dyspnea, 
fatigue, and pain under TML with K = 1, the AICSurv|Long’s computed from AIC−AICLong 
using PROC NLMIXED were 2210.94, 2223.57, 2217.17, 2205.12, and 2200.94, while 
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those obtained by the Monte Carlo method with an MC sample of size 10,000 were 2211.00, 
2223.58, 2217.17, 2205.09, and 2200.93, respectively, which empirically validates the AIC 
obtained from PROC NLMIXED. Due to the nature of the joint model, there are more 
random effects in SPMQ than SPML, and hence, the computations for SPMQ are much 
more intensive than that for SPML. When the patients were followed much longer for the 
survival times than for the longitudinal outcomes, we used a constant extrapolation afiter the 
time of the last observed longitudinal outcome for the trajectory  to adjust the hazard 
functions for all TM’s and TS. The results shown in Table 2 empirically confrm that the 
NLMIXED procedure is quite reliable in computing the MLEs of the parameters in the joint 
model and they are robust with respect to the dimension of the model parameters. Finally, 
we note that each simulation with 500 simulated datasets took about l hour on a Dell PC 
with an Intel i5 processor, 2.40 GHz CPU, and 6 GB of memory. The SAS macros are 
available from the authors upon request.
In our simulation study, we observed that ΔAICSurv and ΔBICSurv correctly identify the true 
survival component in the joint model. In the analysis of the EMPHACIS data, we showed 
that the survival model with K = 2 fit the data the best along with SPML and TMQ. There 
are several potential extensions of the proposed method. The proposed methodology would 
be quite useful in situations where we wish to simultaneously jointly model a multivariate 
longitudinal marker, such as several PRO outcomes, with a time-to-event outcome, such as 
PFS. The proposed ΔAICSurv and ΔBICSurv can be very useful in this context as they can tell 
us about the overall contribution of the multivariate longitudinal marker to the fit of the 
survival data. The proposed methodology is also useful for multivariate survival data, such 
as PFS and OS for example, and then ΔAICSurv and ΔBICSurv can be used in assessing the 
contribution of the longitudinal data to the fit of the multivariate survival data. Finally, 
ΔAICSurv and ΔBICSurv can also be used in joint models for multivariate longitudinal and 
multivariate survival data and hence identify the combinations of longitudinal outcomes that 
are most highly associated with a multivariate time-to-event. These extensions are currently 
under investigation.
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Appendix: Proofs of Theorems
Proof of Theorem 4.1
Let Dobs = {(Yi,ti,δi,zi, xi), i =1,…,n} denote the observed data. We frst observe that
(A.1)
Using (4.3) and (A.1), the joint likelihood for all subjects is given by
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Taking -2log of (A.2) yields
(A.
3)
The AIC decomposition in (4.6) directly follows from (4.4) and (A.3), which completes the 
proof.
Proof of Theorem 4.2
Since AICSurv,0 depends on the survival data alone and BICSurv|Long = AICSurv|Long + 
dim(φ2)(log n − 2), it is sufcient to show
Let Yi =(Yi(ai1),…,Yi(aimi))′ and  denote the original and 
transformed longitudinal outcomes, respectively. Then we have , where 
. Write , where Wi1 is a mi × (q + 1) matrix and 
Wi2 is a mi × (p + 1) matrix. The conditional density of Yi is given by
where Imi is the mi × mi identity matrix. We then obtain
Write , ,  and . Let 
, , 
 and . Since θi ~ N (θ, ∑), we have
(A.4)
Similar to (3.2), we write the hazard function corresponding to Y_^{i ;* _^} as
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where λ0*(t) is the baseline hazard function, which is assumed to take the same form as λ0(t) 
given by (3.4). Then complete-data likelihood function for the survival component in (3.5) 
under the transformed longitudinal data becomes
(A.
6)
By comparing (A.4) and (A.5) to (4.1), (4.2), and (3.2), we obtain that  for 
SPM,  for TM, β* = cβ, and α* = α.
Let  and  denote the MLEs of the model parameters under 
the original longitudinal data and the transformed longitudinal data coupled with the same 
survival data, respectively. Using the transformation invariance principle of MLE, we have 
, , , ,  for 
SPM,  for TM,  and .
Corresponding to  and , we write  and 
. Write  and . Let  and 
. The conditional distribution of the random effects θi given the original 
longitudinal data takes the form
(A.7)
and the corresponding density is given by
(A.
8)
Note that  and 
. Replacing the original data and parameters with the transformed ones 
in (A.7) yields
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and the conditional density of θ*i is given by
(A.
10)




Using (A.11) and (A.12), we have AICSurv|Long (b, c)
which completes the proof.
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Boxplots of the ΔAICSurv differences ((a), (b), and (c)) and the ΔBICSurv differences ((d) 
and (e)) between the true and competing models.
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The diagrams of the MLEs of λ, AICSurv|Long and BICSurv|Long with various values of K 
under SPML for pain.
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Plots of ΔAICSurv (a) and ΔBICSurv (b) under the SPML, SPMQ, SPMQL, TML, TMQ, 
TMQL, TVC, and TS models with K = 2.
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Table 1





Covariates Race: White 189 (91%) 202 (93%)
Gender: Male 169 (81%) 177 (82%)
Age: ≥ 65 80 (38%) 83 (38%)
Karnofsky: High (90-100) 112 (54%) 124 (57%)
Stage: I/II 48 (23%) 46 (21%)
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Table 2
Parameter estimates of SPML and SPMQ in Simulations I and II
Simulation Param. True EST SE SD RMSE CP
I α −0.4 −0.399 0.105 0.104 0.104 0.956
γ 0.05 0.050 0.087 0.088 0.088 0.950
β 1 0.3 0.301 0.067 0.066 0.066 0.960
β 2 1.2 1.211 0.246 0.234 0.234 0.958
σ 0.5 0.500 0.008 0.008 0.008 0.954
logλ −1.7 −1.700 0.076 0.076 0.076 0.964
θ 0 −0.01 −0.007 0.063 0.063 0.063 0.944
θ 1 0.08 0.079 0.014 0.014 0.014 0.934
Σ 00 0.7 0.698 0.058 0.058 0.058 0.936
Σ 10 −0.03 −0.030 0.013 0.013 0.013 0.944
Σ 11 0.06 0.059 0.006 0.006 0.006 0.930
II α −0.4 −0.411 0.113 0.116 0.116 0.946
γ 0.03 0.033 0.088 0.086 0.086 0.956
β 1 0.3 0.307 0.075 0.076 0.077 0.946
β 2 1 0.994 0.142 0.146 0.146 0.938
β 3 5 4.989 0.209 0.211 0.211 0.942
σ 0.5 0.499 0.009 0.009 0.009 0.952
logλ −1.7 −1.690 0.082 0.081 0.082 0.942
θ 0 −0.02 −0.022 0.065 0.067 0.067 0.936
θ 1 0.1 0.097 0.037 0.038 0.038 0.950
θ 2 −0.1 0.099 0.017 0.017 0.017 0.944
Σ 00 0.7 0.700 0.063 0.062 0.062 0.954
Σ 10 −0.08 −0.080 0.037 0.038 0.038 0.952
Σ 11 0.3 0.298 0.039 0.038 0.038 0.968
Σ 20 0.01 0.009 0.016 0.016 0.016 0.942
Σ 21 −0.05 −0.049 0.014 0.013 0.013 0.946
Σ 22 0.1 0.099 0.008 0.008 0.008 0.936






















Zhang et al. Page 27
Table 3
Mean of ΔAICSurv (ΔBICSurv) and frequency of ranking each model as best based on ΔAICSurv (ΔBICSurv)
ΔAICSurv ΔBICSurv
Simulation Model Mean Frequency Mean Frequency
I SPML 42.55 380 34.57 231
TML 38.38 76 34.39 181
TS 38.16 32 34.17 70
TVC 30.70 12 26.71 18
II SPML 588.66 29 580.68 136
SPMQ 596.68 471 584.70 364
TML 419.99 0 416.00 0
TMQ 419.52 0 415.53 0
TS 418.56 0 414.57 0
TVC 399.51 0 395.52 0
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Table 4
AICs and BICs for models with K = 2
Model Anorexia Cough Dyspnea Fatigue Pain
SPML AIC 14205.13 14451.48 12101.25 13184.26 13030.39
AICLong 12017.95 12248.34 9912.26 11005.53 10868.55
ΔAICSurv 19.11 3.15 17.30 27.56 44.46
BIC 14302.38 14548.73 12198.50 13281.51 13127.64
BICLong 12070.63 12301.02 9964.94 11058.20 10921.23
ΔBICSurv 11.01 −4.95 9.20 19.45 36.35
SPMQ AIC 14123.05 14250.06 11908.13 13058.18 12778.41
AICLong 11933.53 12046.68 9714.28 10873.93 10610.07
ΔAICSurv 16.77 2.91 12.44 22.04 37.95
BIC 14240.57 14367.57 12025.64 13175.69 12895.92
BICLong 12002.42 12115.56 9783.17 10942.82 10678.96
ΔBICSurv 4.62 −9.25 0.29 9.89 25.80
SPMQL AIC 14124.36 14251.34 11911.54 13057.48 12788.89
AICLong 11933.24 12046.45 9713.94 10873.82 10609.26
ΔAICSurv 15.17 1.40 8.70 22.63 26.67
BIC 14237.82 14364.80 12025.00 13170.94 12902.35
BICLong 12002.12 12115.34 9782.83 10942.70 10678.15
ΔBICSurv 7.06 −6.70 0.60 14.53 18.56
TML AIC 14204.92 14449.26 12106.26 13185.81 13038.62
AICLong 12017.75 12248.29 9911.77 11005.07 10867.68
ΔAICSurv 19.12 5.32 11.81 25.56 35.35
BIC 14298.12 14542.46 12199.45 13279.01 13131.82
BICLong 12070.43 12300.97 9964.45 11057.75 10920.36
ΔBICSurv 15.07 1.27 7.76 21.50 31.30
TMQ AIC 14118.40 14244.30 11904.94 13049.48 12773.67
AICLong 11933.39 12046.50 9713.94 10873.95 10609.29
ΔAICSurv 21.29 8.50 15.29 30.77 41.92
BIC 14227.80 14353.70 12014.34 13158.89 12883.07
BICLong 12002.27 12115.39 9782.82 10942.84 10678.17
ΔBICSurv 17.23 4.45 11.24 26.72 37.86
TMQL AIC 14128.97 14254.40 11916.77 13067.97 12805.13
AICLong 11933.74 12046.45 9713.94 10874.12 10609.33
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Model Anorexia Cough Dyspnea Fatigue Pain
ΔAICSurv 11.07 −1.65 3.47 12.45 10.49
BIC 14238.38 14363.81 12026.18 13177.38 12914.54
BICLong 12002.63 12115.34 9782.83 10943.01 10678.21
ΔBICSurv 7.02 −5.70 −0.58 8.40 6.44
TS ΔAICSurv 18.45 5.17 11.55 24.77 34.32
ΔBICSurv 14.40 1.11 7.50 20.72 30.27
TVC ΔAICSurv 19.52 4.25 15.04 27.76 48.60
ΔBICSurv 15.47 0.20 10.99 23.71 44.54


































































































































































































































































































































































































































































































































































































































































































Zhang et al. Page 31
Table 6
Estimates for the survival components of TMs with K = 2
Longitudinal
Symptom
α* α 1 β 
Model HR P-value HR P-value HR P-value
TML Anorexia 0.631 <.0001 0.609 <.0001 1.365 <.0001
Cough 0.650 <.0001 0.647 <.0001 1.194 0.0056
Dyspnea 0.642 <.0001 0.655 <.0001 1.255 0.0002
Fatigue 0.630 <.0001 0.627 <.0001 1.417 <.0001
Pain 0.628 <.0001 0.655 <.0001 1.464 <.0001
TMQ Anorexia 0.629 <.0001 0.607 <.0001 1.409 <.0001
Cough 0.647 <.0001 0.642 <.0001 1.237 0.0010
Dyspnea 0.640 <.0001 0.657 <.0001 1.291 <.0001
Fatigue 0.628 <.0001 0.626 <.0001 1.486 <.0001
Pain 0.635 <.0001 0.655 <.0001 1.504 <.0001
TMQL Anorexia 0.630 <.0001 0.621 <.0001 1.164 0.0008
Cough 0.650 <.0001 0.650 <.0001 1.019 0.5561
Dyspnea 0.640 <.0001 0.645 <.0001 1.089 0.0220
Fatigue 0.629 <.0001 0.628 <.0001 1.161 0.0003
Pain 0.642 <.0001 0.649 <.0001 1.135 0.0007
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